...
首页> 外文期刊>Advanced Pharmaceutical Bulletin >Preparation and Bioavailability Analysis of Ferrous Bis Alanine Chelate as a New Micronutrient for Treatment of Iron Deficiency Anemia
【24h】

Preparation and Bioavailability Analysis of Ferrous Bis Alanine Chelate as a New Micronutrient for Treatment of Iron Deficiency Anemia

机译:亚铁双丙氨酸亚铁螯合剂作为新型微量营养素治疗缺铁性贫血的制备及生物利用度分析

获取原文
           

摘要

Purpose: One of the most nutritional disorders around the world is iron deficiency. A novel iron compound was synthesized by chelating ferrous ions with alanine for prevention and treatment of iron deficiency anemia. Methods: The newly synthesized compound was characterized both qualitatively and quantitatively by Fourier Transform Infrared (FT-IR) spectroscopy. The bioavailability of newly synthesized iron micronutrient was evaluated in four groups of Wistar rats. The group I was a negative control group and the other three groups received three different iron formulations. After 14 days, the blood samples were taken and analyzed accordingly. Results: Calculations showed that more than 91.8% of iron was incorporated in the chelate formulation. In vivo studies showed that serum iron, total iron binding capacity and hemoglobin concentrations were significantly increased in group IV, which received ferrous bis alanine chelate compared with the negative control group (p<0.05) and also group II, which received ferrous sulfate.7H2O (p<0.05). It indicates that the new formulation considerably improves the blood iron status compared with the conventional iron compounds. There were no significant differences (p<0.05) in the serum iron between group IV and group III, which received ferrous bis glycine. Conclusion: The results showed better bioavailability of ferrous bis alanine as a new micronutrient for treatment of iron deficiency anemia in comparison with ferrous sulfate. Ferrous bis alanine could be considered as a suitable supplement for prevention and treatment of iron deficiency anemia.
机译:目的:世界上最营养的疾病之一是铁缺乏症。通过将亚铁离子与丙氨酸螯合合成了一种新型的铁化合物,用于预防和治疗缺铁性贫血。方法:采用傅立叶变换红外光谱(FT-IR)对新合成的化合物进行定性和定量表征。在四组Wistar大鼠中评估了新合成的铁微量营养素的生物利用度。第一组是阴性对照组,其他三组接受了三种不同的铁制剂。 14天后,采集血样并进行相应分析。结果:计算表明,螯合剂配方中掺入了超过91.8%的铁。体内研究表明,与阴性对照组相比,接受双丙氨酸亚铁螯合亚铁螯合的IV组与接受硫酸亚铁的II组相比,血清铁,总铁结合能力和血红蛋白浓度显着增加(p <0.05)7H2O。 (p <0.05)。这表明与传统的铁化合物相比,新配方大大改善了血铁状态。接受亚铁双甘氨酸的IV组和III组之间的​​血清铁无显着差异(p <0.05)。结论:结果表明,与硫酸亚铁相比,双丙氨酸亚铁作为一种新型微量营养素可治疗缺铁性贫血,具有更高的生物利用度。双丙氨酸亚铁可以被认为是预防和治疗缺铁性贫血的合适补充剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号